Loading clinical trials...
Loading clinical trials...
A Phase-2b Controlled Study to Evaluate the Humoral and Cellular Immune Response and Safety Following One and Two Doses of an Adjuvanted RSV Subunit Vaccine in Immunocompromised Patients Aged 18 Years and Older.
Conditions
Interventions
Arexvy powder and suspension for injection
Locations
1
Austria
Institute of Specific Prophylaxis and Tropical Medicine, CePII, Medical university of Vienna
Vienna, Austria
Start Date
September 19, 2024
Primary Completion Date
August 31, 2025
Completion Date
March 31, 2026
Last Updated
November 27, 2024
NCT03596801
NCT06583031
NCT04520659
NCT06585150
NCT05568706
NCT06917508
Lead Sponsor
Medical University of Vienna
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions